Nerve Growth Factor

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Nerve Growth Factor
Accession Number
DB12620
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Nerve Growth Factor has been used in trials studying the prevention and treatment of Mental Handicap, Alzheimer's Disease, Traumatic Brain Injury, Cerebral Palsy Children, and Delayed Speech Development, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
V7FWP1D62O
CAS number
9061-61-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911353
RxNav
7327
Wikipedia
Nerve_growth_factor

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceHealthy Volunteers / Hyperalgesia1
0CompletedBasic ScienceHealthy Volunteers / Hyperalgesia / Muscle Hypersensitivity / Pain Response1
0RecruitingBasic ScienceHealthy Volunteers / Hyperalgesia / Pain Response1
1CompletedBasic ScienceHealthy Volunteers1
1RecruitingTreatmentInjury of Optic Nerve1
1Unknown StatusTreatmentAlzheimer's Disease (AD)1
1, 2CompletedTreatmentCorneal Inflammation / Neurotrophic Keratitis / Ulcerative keratitis1
1, 2CompletedTreatmentRetinitis Pigmentosa (RP)1
2Active Not RecruitingTreatmentCystoid Macular Edema / Retinitis Pigmentosa (RP)1
2CompletedPreventionHypoxic-Ischaemic Encephalopathy1
2CompletedTreatmentDry Eye Syndrome (DES)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Peripheral Nervous System Diseases1
2CompletedTreatmentTraumatic Brain Injury (TBI)1
2Not Yet RecruitingTreatmentAlcohol-induced Brain Injury1
2Unknown StatusTreatmentCerebral Palsy Children / Children With Traumatic Brain Injury / Delayed Speech Development / Mental Handicap1
4RecruitingTreatmentCerebral Small Vessels Disease1
Not AvailableCompletedNot AvailableNeurotrophic Keratopathy1
Not AvailableCompletedBasic ScienceAbnormality of SSEPs / Exercises / Hyperalgesia / Motor Activities / Nerve Growth Factors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 17:15 / Updated on March 01, 2020 21:16

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates